Nexium Lawsuit: Kidney Claims, $425M Settlement and 2026 Status
A Nexium lawsuit is a legal claim against AstraZeneca saying that its heartburn drug Nexium (esomeprazole) caused a serious injury, most often kidney damage. Thousands of these claims ran through a federal court in New Jersey for years. In October 2023, AstraZeneca agreed to pay $425 million to resolve its pending kidney cases. It admitted no wrongdoing. Other drug makers in the same litigation settled too. So where do things stand as of November 2026, and can you still file? This guide explains the injuries, FDA warnings, key dates, and the separate Nexium antitrust case. This article is general information, not legal or medical advice.
| Quick fact | Details (as of November 2026) |
|---|---|
| Drug | Nexium (esomeprazole magnesium), a proton pump inhibitor (PPI) |
| Brand maker | AstraZeneca |
| Main federal case | In re Proton-Pump Inhibitor Products Liability Litigation (No. II), MDL No. 2789 |
| Court and judge | U.S. District Court for the District of New Jersey, Judge Claire C. Cecchi |
| Main injuries alleged | Chronic kidney disease, acute kidney injury, acute interstitial nephritis, kidney failure |
| AstraZeneca settlement | $425 million, announced October 3, 2023, no admission of liability |
| Other settling makers | GSK, Procter & Gamble, Pfizer (earlier) and Takeda (2024) |
What is a Nexium lawsuit about?
Most Nexium lawsuits claim the drug harmed the kidneys and that the maker did not warn patients and doctors well enough. These are product liability claims, usually built on failure to warn, design defect, and negligence theories.
Nexium belongs to a drug class called proton pump inhibitors, or PPIs. PPIs lower stomach acid. Doctors prescribe them for acid reflux (GERD), erosive esophagitis, ulcers, and other acid problems. A lower-dose version is also sold over the counter. Other common PPIs include Prilosec (omeprazole), Prevacid (lansoprazole), and Dexilant (dexlansoprazole).
Plaintiffs argued that long-term PPI use raised the risk of kidney disease, sometimes without any warning signs. The drug makers denied those claims. They said their labels were adequate and that the science did not prove PPIs cause chronic kidney disease.
Because the claims involved several brands, federal courts grouped them together. That group became the PPI multidistrict litigation (MDL) in New Jersey. You can browse similar cases in our lawsuit category.
What injuries do Nexium lawsuits claim?
The lawsuits mainly claim kidney injuries. The most common were chronic kidney disease, acute kidney injury, and acute interstitial nephritis. Some severe cases involved end-stage kidney failure that required dialysis or a transplant.
| Alleged injury | What it means | Why it matters in court |
|---|---|---|
| Acute interstitial nephritis (AIN) | Sudden swelling of the tissue between the kidney’s filtering tubes, often an allergic-type reaction | It is named in the Nexium warning label, which gives plaintiffs a clearer link |
| Acute kidney injury (AKI) | A sudden drop in kidney function over hours or days | Plaintiffs argued AIN can lead to AKI if it goes unnoticed |
| Chronic kidney disease (CKD) | Slow, lasting loss of kidney function over months or years | The label does not list CKD as a warning, so causation was hotly disputed |
| End-stage renal disease | Kidney failure that needs dialysis or a transplant | The most serious claims and usually the highest-value cases |
A key point: researchers have reported links between long-term PPI use and kidney problems in observational studies. An association, however, does not prove that the drug caused a specific person’s injury. That gap is exactly what both sides fought over.

What did the FDA say about Nexium and the kidneys?
The FDA-approved Nexium label warns about acute tubulointerstitial nephritis, another name for acute interstitial nephritis. It tells doctors to stop Nexium and evaluate patients if they suspect this condition. It does not list chronic kidney disease as a warning.
The AIN warning was added to PPI labels in the mid-2010s. The Nexium label revised in December 2016 already listed it in the Highlights section. The current label notes that this kidney problem can appear at any point during PPI therapy.
The 2022 Nexium prescribing information also warns about other risks. These include C. difficile diarrhea, bone fractures, low magnesium, vitamin B-12 deficiency, lupus, severe skin reactions, and fundic gland polyps.
What about stomach cancer? The label has a warning called “Presence of Gastric Malignancy.” It means that symptom relief from Nexium does not rule out stomach cancer. It is not a statement that Nexium causes cancer. AstraZeneca has separately reported defending some lawsuits that allege gastric cancer after PPI use.
What happened in the PPI multidistrict litigation?
The federal PPI cases were combined into MDL No. 2789 in August 2017 before Judge Claire C. Cecchi in New Jersey. Over the years, the drug makers settled one by one instead of going to a full jury verdict.
An MDL is not a class action. Each person keeps an individual case, but the cases share pretrial work and “bellwether” test trials.
The first AstraZeneca bellwether trial was set for November 28, 2023. In September 2023, the court postponed it. A few weeks later, AstraZeneca announced its settlement.
According to the federal Judicial Panel on Multidistrict Litigation, the MDL had received 18,706 actions in total by December 2025. The panel’s August 3, 2026 report still listed 11,321 actions as pending. The reports do not say how many of those cases are already part of a settlement and simply waiting to be closed.

What is the timeline of the Nexium litigation?
Here are the main verified dates, from the antitrust case to the latest federal court count.
| Date | Event |
|---|---|
| December 5, 2014 | A federal jury in Massachusetts rules for AstraZeneca and Ranbaxy in the Nexium antitrust (“pay-for-delay”) trial |
| November 21, 2016 | The First Circuit Court of Appeals affirms the antitrust verdict |
| August 2017 | Federal PPI kidney cases are centralized as MDL No. 2789 in New Jersey |
| Before October 2023 | GSK, Procter & Gamble, and Pfizer settle PPI claims, reportedly for more than $100 million combined |
| September 14, 2023 | Court postpones the first AstraZeneca bellwether trial, set for November 28, 2023 |
| October 3, 2023 | AstraZeneca announces a $425 million settlement of Nexium and Prilosec claims |
| April 2024 | Takeda reaches an agreement in principle on U.S. Prevacid and Dexilant claims |
| November 2024 | Takeda signs the final settlement agreement; terms are confidential |
| August 3, 2026 | Federal panel lists 11,321 actions still pending in MDL No. 2789 |
What did the $425 million AstraZeneca settlement cover?
The settlement resolved all pending claims against AstraZeneca in the federal MDL, plus all pending claims in Delaware and New Jersey state courts. It covered both Nexium and Prilosec. AstraZeneca did not admit liability.
AstraZeneca’s own financial reports describe a $425 million provision for this litigation. Plaintiffs’ lead lawyers said the deal resolved about 11,000 claims.
The deal did not end every case. In early 2024, AstraZeneca reported that one case remained in a Louisiana federal court. That case alleged gastric cancer, not kidney injury. Its trial, once set for April 2024, was postponed with no new date. We could not confirm its outcome as of November 2026.
Other makers settled on their own. Takeda, which sells Prevacid and Dexilant, said more than 6,100 suits had been filed against it by March 2024. It signed a confidential settlement in November 2024.
Was there a Nexium antitrust lawsuit too?
Yes. A separate case, In re Nexium (Esomeprazole) Antitrust Litigation, had nothing to do with injuries. It was about drug prices and generic competition.
Drug buyers claimed AstraZeneca paid generic makers, including Ranbaxy, to delay cheaper generic Nexium, a so-called “pay-for-delay” deal.
On December 5, 2014, a federal jury in Massachusetts ruled for AstraZeneca and Ranbaxy. The jury found the payment to Ranbaxy was large and unjustified. Even so, it decided that Ranbaxy would not have entered the market earlier without the deal. So the buyers could not prove harm. The First Circuit upheld the verdict in November 2016.
Who may still qualify for a Nexium lawsuit?
As of November 2026, the big kidney settlements cover cases that were already pending when the deals were made. A new claim faces real hurdles, especially deadlines.
In general, a lawyer would look at these points:
- You took Nexium or another PPI, usually for a long time, and can show it with pharmacy or medical records.
- A doctor diagnosed a kidney injury, such as AIN, AKI, CKD, or kidney failure.
- Your medical records support a link between the drug and the injury.
- Your claim is still within your state’s statute of limitations.
Each state sets its own deadline for injury claims, often between one and six years. Many states start the clock when you knew, or should have known, that the drug may have caused your injury. Because the kidney warning has been public for years, deadlines can be tight. Speak with a licensed attorney in your state about your own timeline.
Drug cases can share similar patterns. For example, our guide to the Taxotere lawsuit explains how another drug-injury MDL handled warning-label claims. For a different kind of injury case, see our head injury lawsuit guide.
What should you do if you take Nexium now?
Do not stop taking Nexium on your own. Talk to your doctor first. Stopping suddenly can bring back symptoms, and your doctor may need to treat an underlying condition.
- Ask your doctor if you still need a PPI, and at what dose.
- Ask whether you need kidney function tests, especially after long-term use.
- Report warning signs such as fever, rash, less urine, swelling, or tiredness.
- Keep records of your prescriptions, diagnoses, and test results.
- If you believe you were harmed, speak with a licensed attorney about deadlines.
Frequently Asked Questions
Is the Nexium lawsuit still open?
Partly. AstraZeneca settled its pending kidney cases in October 2023. However, the federal PPI MDL was still listed with 11,321 pending actions in August 2026, and AstraZeneca reported a gastric cancer case still pending in early 2024.
How much is a Nexium settlement worth per person?
No official per-person amount has been published. The $425 million total covered about 11,000 claims, but payouts depend on injury severity and individual facts. Simple division does not show what any one person received.
Did AstraZeneca admit Nexium causes kidney disease?
No. AstraZeneca denied the claims and admitted no wrongdoing. The settlement only ended the litigation.
Does Nexium have an FDA kidney warning?
Yes, for acute tubulointerstitial nephritis. The label does not list chronic kidney disease as a warning.
Is the Nexium antitrust case the same as the injury case?
No. The antitrust case dealt with alleged pay-for-delay deals and drug prices. A jury ruled for AstraZeneca in 2014.
Can I still file a Nexium kidney claim?
Possibly, but deadlines vary by state and may have passed. A licensed attorney can review your dates and records.
Conclusion
The Nexium lawsuit story has two parts. The injury side centered on kidney claims in MDL No. 2789. It largely wound down after AstraZeneca’s $425 million settlement in 2023 and deals by GSK, Procter & Gamble, Pfizer, and Takeda. The antitrust side ended with a 2014 jury verdict for AstraZeneca, upheld on appeal in 2016. As of November 2026, a new kidney claim faces tight deadlines. If you take Nexium, keep using it as prescribed until you talk with your doctor, and ask about kidney monitoring. If you think the drug harmed you, a licensed attorney in your state can tell you whether you still have time to act.
